PI3K Inhibitor Solid Forms for Scalable Crystallization Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing PI3K inhibitors lack scalability, efficiency, and consistency in solid state characteristics, which affect the quality, safety, and efficacy of drug products, necessitating a need for a process that is safe, scalable, and economically viable.
Innovation Solution
Development of solid forms of PI3K inhibitors, including crystalline forms, hydrates, anhydrates, solvates, and cocrystals, with improved properties such as powder flow, compaction, and stability, suitable for pharmaceutical formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current methods for producing PI3K inhibitors are used, then the production process can be maintained, but scalability and efficiency are insufficient
Solution Approach 1:
The patent modifies reaction parameters including temperature, solvent composition, and pH conditions to optimize the synthesis process. These parameter changes enable scalable production while maintaining high efficiency and consistent solid state characteristics of the PI3K inhibitor product
Solution Approach 2:
The patent utilizes phase transition during crystallization to produce consistent solid forms of the PI3K inhibitor. By controlling the phase transition from solution to solid state through temperature and solvent management, the process achieves both scalability and efficiency while ensuring product quality
2Stability of the object's composition
If current production methods are used, then existing processes can be maintained, but consistency in solid state characteristics is insufficient
Solution Approach 1:
The patent precisely controls reaction parameters including temperature gradients, solvent ratios, and pH levels to ensure consistent solid state characteristics. These controlled parameter changes produce reproducible crystal forms with consistent polymorphic properties across manufacturing batches
Solution Approach 2:
The patent implements monitoring and control mechanisms to track solid state characteristics during production. By measuring and adjusting parameters in real-time based on observed solid form development, the process maintains consistent product quality and polymorphic stability
3Ease of manufacture
If current production methods are used, then existing processes can be maintained, but economic viability is compromised
Solution Approach 1:
The patent employs cost-effective solvents and reagents that can be easily removed or recycled, reducing manufacturing costs. The process uses inexpensive, readily available materials while maintaining high productivity through optimized reaction conditions that minimize waste and maximize yield
Solution Approach 2:
The patent optimizes reaction conditions to improve yield and reduce processing time, directly enhancing productivity. By adjusting parameters such as temperature, concentration, and reaction time, the process achieves both economic viability through reduced material costs and improved manufacturing efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solid forms provide enhanced manufacturing properties and therapeutic efficacy, enabling the production of stable and effective PI3K inhibitor formulations for treating various diseases.
Implementation Method 1
Development of solid forms of PI3K inhibitors, including crystalline forms, hydrates, anhydrates, solvates, and cocrystals
Data Source
AI summary
Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphic forms, cocrystals, and amorphous forms thereof, and pharmaceutical compositions thereof.